Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Combining two cancer immunotherapeutics – Bristol-Myers Squibb's Opdivo and Yervoy – has achieved unprecedented efficacy in a landmark melanoma study.

Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion. The offer – which is a 62% premium over Array’s closing share price on Friday ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Hikma said Tyzavan is the only FDA-approved vancomycin product commercially available for all patients that is available at room temperature and requires no compounding, thawing, activation or ...

Novartis (NVS) reported $14.05 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.2%. EPS of $2.42 for the same period compares to $1.97 a year ago. The ...

Novartis moves to block cancer drug generic in US ...